Literature DB >> 24079740

A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice.

Iwao Arai1, Minoru Tsuji, Hiroshi Takeda, Nobutake Akiyama, Saburo Saito.   

Abstract

We investigated the effects of a single dose of mouse interleukin-31 (IL-31) on scratching behaviour in comparison with spontaneous skin-lesion- or serotonin (5-HT)- induced scratching behaviour in NC/Nga and BALB/c mice. Intradermal (i.d.) injection of IL-31 caused a gradual increase in long-lasting scratching (LLS, over 1.5 s) about 3 h after administration followed by a gradual decrease for over 24 h after administration. I.d. injection of IL-31 significantly increased the total LLS counts/24 h but not short-lasting scratching (SLS, 0.3-1.5 s). In skin-lesioned NC/Nga mice, the LLS but not SLS counts were significantly higher than those in non-skin-lesioned NC/Nga mice. We also investigated 5-HT-induced scratching in BALB/c mice, SLS but not LLS increased immediately after the injection and then decreased to baseline after at 20 min. These results suggest that IL-31 may participate in the sensation of itching and promote scratching behaviour in skin-lesioned NC/Nga mice, an animal model of atopic dermatitis (AD).
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-31; itch; pruritogen; scratch; serotonin

Mesh:

Substances:

Year:  2013        PMID: 24079740     DOI: 10.1111/exd.12222

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  22 in total

1.  Agreeableness and Self-Consciousness as Predictors of Induced Scratching and Itch in Patients with Psoriasis.

Authors:  C Schut; S Muhl; K Reinisch; A Claßen; R Jäger; U Gieler; J Kupfer
Journal:  Int J Behav Med       Date:  2015-12

Review 2.  Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.

Authors:  N Landolina; F Levi-Schaffer
Journal:  Br J Pharmacol       Date:  2016-02-01       Impact factor: 8.739

Review 3.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

4.  Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Authors:  Saadet Inan; Alan Cowan
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Interleukin-31: a novel diagnostic marker of allergic diseases.

Authors:  Anja Rabenhorst; Karin Hartmann
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

6.  Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.

Authors:  K Kasutani; E Fujii; S Ohyama; H Adachi; M Hasegawa; H Kitamura; N Yamashita
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

7.  The Itch-Scratch Cycle: A Review of the Mechanisms.

Authors:  Giulia Rinaldi
Journal:  Dermatol Pract Concept       Date:  2019-04-30

8.  Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.

Authors:  Timothy J Fleck; Lori R Norris; Sean Mahabir; Rodney R Walters; Olivier Martinon; Steven A Dunham; Andrea J Gonzales
Journal:  Vet Dermatol       Date:  2021-04-08       Impact factor: 1.867

9.  IL-31 is overexpressed in lichen planus but its level does not correlate with pruritus severity.

Authors:  Kalina Welz-Kubiak; Anna Kobuszewska; Adam Reich
Journal:  J Immunol Res       Date:  2015-02-03       Impact factor: 4.818

Review 10.  Advances in understanding itching and scratching: a new era of targeted treatments.

Authors:  Kristen M Sanders; Leigh A Nattkemper; Gil Yosipovitch
Journal:  F1000Res       Date:  2016-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.